Background: CIP can improve glycemic control and quality of life for people with diabetes on multiple daily injections (MDI). Despite its benefits, providers may sub optimally prescribe CIP. The purpose of this study is to use quality improvement methods to successfully implement a validated attitude assessment to foster SDM conversations around CIP.

Method: The T1D Exchange recruited seven pediatric and adult diabetes centers to participate in this project from June - November 2022. The centers applied QI principles to implement the Diabetes Technology Attitude (DTA) questionnaire, a validated tool to facilitate SDM conversations. Positive responses prompted discussion about CIP. Each center contributed their data from a sample of people with Type 1 Diabetes (T1D) and Type 2 Diabetes on Insulin (T2D) who responded to the DTA.

Result: Eighty-eight people with diabetes and CGM but not on CIP naive completed the SDM tool. Over 70% of both T1D and T2D patients agreed that diabetes technology made their lives easier, does ‘more good than bad,’ and that they feel lucky to live in a time with so much technology (Figure 1). Sixty-nine percent of the cohort were prescribed CIP as a result of intentional SDM conversations based on the DTA results.

Conclusion: Validated SDM tools, such as DTA, can be a viable, low burden strategy to introduce conversations on the use of diabetes technology like CIP in clinical practice.


O.Odugbesan: None. A.K.Myers: Research Support; Neurocrine Biosciences, Inc. O.Ebekozien: Advisory Panel; Medtronic, Research Support; Eli Lilly and Company, Dexcom, Inc. D.T1d exchange quality improvement collaborative (t1: n/a. N.A.Xavier: Employee; Eli Lilly and Company, Speaker's Bureau; Boehringer Ingelheim and Eli Lilly Alliance. T.Wright: None. G.Nelson: None. J.Friedman: None. G.Aleppo: Advisory Panel; Medscape, Consultant; Bayer Inc., Insulet Corporation, Research Support; Dexcom, Inc., Eli Lilly and Company, Emmes, Insulet Corporation, Fractyl Health, Inc., WellDoc, Speaker's Bureau; Dexcom, Inc. G.O'malley: Research Support; Dexcom, Inc., Abbott Diabetes, Tandem Diabetes Care, Inc., Omnipod, Eli Lilly and Company. A.M.Mckee: Advisory Panel; Medtronic, Novo Nordisk. B.Miyazaki: None.


Eli Lilly and Company

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at